These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 28596091)

  • 61. Gender-neutrality, herd effect and resilient immune response for sustainable impact of HPV vaccination.
    Lehtinen M; Apter D
    Curr Opin Obstet Gynecol; 2015 Oct; 27(5):326-32. PubMed ID: 26308204
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prevention of HPV-related cancers in Norway: cost-effectiveness of expanding the HPV vaccination program to include pre-adolescent boys.
    Burger EA; Sy S; Nygård M; Kristiansen IS; Kim JJ
    PLoS One; 2014; 9(3):e89974. PubMed ID: 24651645
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development.
    Pinto LA; Dillner J; Beddows S; Unger ER
    Vaccine; 2018 Aug; 36(32 Pt A):4792-4799. PubMed ID: 29361344
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
    Cody P; Tobe K; Abe M; Elbasha EH
    BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US.
    Dunne EF; Datta SD; E Markowitz L
    Cancer; 2008 Nov; 113(10 Suppl):2995-3003. PubMed ID: 18980283
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Developments in L2-based human papillomavirus (HPV) vaccines.
    Schellenbacher C; Roden RBS; Kirnbauer R
    Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The Development of Human Papillomavirus (HPV) Vaccines and Current Barriers to Implementation.
    Butterfield R; Dhanani S
    Immunol Invest; 2021 Oct; 50(7):821-832. PubMed ID: 33724139
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Assessing the cost-effectiveness of HPV vaccination strategies for adolescent girls and boys in the UK.
    Datta S; Pink J; Medley GF; Petrou S; Staniszewska S; Underwood M; Sonnenberg P; Keeling MJ
    BMC Infect Dis; 2019 Jun; 19(1):552. PubMed ID: 31234784
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Asking about human papillomavirus vaccination and the usefulness of registry validation: a study of young women recruited using Facebook.
    Gunasekaran B; Jayasinghe Y; Brotherton JM; Fenner Y; Moore EE; Wark JD; Fletcher A; Tabrizi SN; Garland SM
    Vaccine; 2015 Feb; 33(6):826-31. PubMed ID: 25444782
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [HPV immunization for the prevention of cervical cancer].
    Mougin C; Bourgault-Villada I; Coursaget P
    Presse Med; 2009 Dec; 38(12):1750-68. PubMed ID: 19765945
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Scientific evidence supporting recommendations on the use of the 9-valent HPV vaccine in a 2-dose vaccine schedule in Australia.
    Wnukowski-Mtonga P; Jayasinghe S; Chiu C; Macartney K; Brotherton J; Donovan B; Hall M; Smith DW; Peterson K; Campbell-Lloyd S; Selvey C; Giles M; Kaldor J; Marshall H;
    Commun Dis Intell (2018); 2020 Apr; 44():. PubMed ID: 32299331
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Challenging 'girls only' publicly funded human papillomavirus vaccination programmes.
    Law VG; Gustafson DL
    Nurs Inq; 2017 Jan; 24(1):. PubMed ID: 27198909
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
    Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
    Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
    [TBL] [Abstract][Full Text] [Related]  

  • 74. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP).
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 May; 59(20):626-9. PubMed ID: 20508593
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Early policy responses to the human papillomavirus vaccine in the United States, 2006-2010.
    Laugesen MJ; Mistry R; Carameli KA; Ribisl KM; Needleman J; Bastani R
    J Adolesc Health; 2014 Nov; 55(5):659-64. PubMed ID: 24928803
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Evidence of effective delivery of the human papillomavirus (HPV) vaccine through a publicly funded, school-based program: the Ontario Grade 8 HPV Vaccine Cohort Study.
    Lim WT; Sears K; Smith LM; Liu G; Lévesque LE
    BMC Public Health; 2014 Oct; 14():1029. PubMed ID: 25278003
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Human papillomavirus vaccination update: Nonavalent vaccine and the two-dose schedule.
    Brotherton JM
    Aust J Gen Pract; 2018 Jul; 47(7):417-421. PubMed ID: 30114867
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Correlates of human papillomavirus vaccine coverage: a state-level analysis.
    Moss JL; Reiter PL; Brewer NT
    Sex Transm Dis; 2015 Feb; 42(2):71-5. PubMed ID: 25585064
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study.
    Simms KT; Steinberg J; Caruana M; Smith MA; Lew JB; Soerjomataram I; Castle PE; Bray F; Canfell K
    Lancet Oncol; 2019 Mar; 20(3):394-407. PubMed ID: 30795950
    [TBL] [Abstract][Full Text] [Related]  

  • 80. From the monovalent to the nine-valent HPV vaccine.
    Pils S; Joura EA
    Clin Microbiol Infect; 2015 Sep; 21(9):827-33. PubMed ID: 25980355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.